|Bid||1.1400 x 1000|
|Ask||1.1500 x 1100|
|Day's Range||1.0900 - 1.1600|
|52 Week Range||0.7400 - 25.6000|
|Beta (3Y Monthly)||2.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against GTx, Inc. (“GTx” or the “Company”) (GTXI) in connection with the proposed sale of GTx to Oncternal Therapeutics, Inc. (“Oncternal”). If you are a GTx shareholder and would like to discuss your legal rights and options, please visit GTx (GTXI) Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email@example.com or firstname.lastname@example.org. As a result, GTx shareholders must be provided with this information in order to adequately assess and value the merger consideration. The lawsuit seeks to enjoin the shareholder vote on the proposed transaction until such information is disclosed.
NEW YORK , April 1, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered ...
Entrepreneurs of all types strive to create new solutions to old problems, and that always comes with risk of failure — and not just with untested drugs. One shouldn’t stop striving to create something new, no matter the industry, just because it might not work out.
NEW YORK, March 20, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Clementia Pharmaceuticals.
“We had a commercial team, a marketing team, and the sales organization. … At the last minute, the FDA decided the data was not sufficient for approval.”
NEW ORLEANS , March 11, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed ...
Do you own shares of GTx, Inc. (NASDAQ CM: GTXI)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of GTx, Inc. (“GTx” or the “Company”) (NASDAQ CM: GTXI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Oncternal Therapeutics, Inc. (“Oncternal”). Under the terms of the agreement, current GTx stockholders will own approximately 25% of the combined company.
NEW YORK, March 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased GTx, Inc. (“GTx” or the “Company”).
CORAL GABLES, FL / ACCESSWIRE / March 7, 2019 / The healthcare stock market has gotten off to an impressive start in the first few months of 2019, as companies in the healthcare sector work to pioneer innovative drug treatment options and care solutions for the millions of patients in need. On a near daily basis, headlines detailing a company's new drug approval or a technological breakthrough emerge, indicating to potential investors that they could benefit from paying attention to the healthcare sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), GTx Inc (GTXI), Co-Diagnostics Inc (CODX), and Novavax Inc (NASDAQ:NVAX) represent 4 healthcare companies heating up on Thursday.
Oncternal does not anticipate retaining any GTx employees once the merger is completed. The biopharmaceutical firm has 27 employees — 25 of them local.
GTx, Inc. (GTXI) and Oncternal Therapeutics, Inc., a privately held clinical-stage biotechnology company developing potential first-in-class therapeutic candidates for cancers with critical unmet medical need, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the majority owners of GTx’s outstanding common stock. The proposed merger will create a publicly-traded, clinical-stage oncology company. The combined company will be named Oncternal Therapeutics, Inc. and plans to change its ticker symbol on the Nasdaq Capital Market to ONCT upon closing of the transaction.
Yesterday, FedEx Logistics, a subsidiary of FedEx Corp., announced plans to move its global headquarters to the former Gibson Guitar Factory building in 2020, joining the likes of some of the area’s largest locally based public companies. To read more on FedEx Logistics and plans for the area, click here, here, or here. This news comes almost exactly a year after home services provider, ServiceMaster Global Holdings relocated its first group of employees from East Memphis to the newly renovated One ServiceMaster Center, formerly the Peabody Place mall.
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 39 cents. The company's shares closed at $1.79. A year ago, they were trading at $7.92. _____ This story was generated by ...
GTx, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update.
The more than 50 current and former executives at Memphis-based public companies earned $180 million in total compensation in 2017.
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / GTx Inc. was seeing big gains on Friday despite any news. The company had recently saw its shares collapse on news that its only drug candidate had failed a mid-stage clinical trial. Shares of TrovaGene Inc. were also in the green despite any news on Friday, but it was last week that the company announced it had entered into an exclusive patent license agreement with the Massachusetts Institute of Technology.
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.